Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder

References

• Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev. (1), CD002795 (2006).
   Google Scholar
• Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs64(4), 383–404 (2004).
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann. Clin. Psychiatry12(2), 101–105 (2000).
   PubMedGoogle Scholar
• Zohar J, Amital D, Miodownik C et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J. Clin. Psychopharmacol.22(2), 190–195 (2002).
   PubMed Web of Science ®Google Scholar
• Southwick SM, Krystal JH, Bremner JD et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry54(8), 749–758 (1997).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry52(12), 1048–1060 (1995).
   PubMed Web of Science ®Google Scholar
• Stein MB, McQuaid JR, Pedrelli P, Lenox R, McCahill ME. Posttraumatic stress disorder in the primary care medical setting. Gen. Hosp. Psychiatry22(4), 261–269 (2000).
   PubMed Web of Science ®Google Scholar
• Gillock KL, Zayfert C, Hegel MT, Ferguson RJ. Posttraumatic stress disorder in primary care: prevalence and relationships with physical symptoms and medical utilization. Gen. Hosp. Psychiatry27(6), 392–399 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez BF, Weisberg RB, Pagano ME et al. Mental health treatment received by primary care patients with posttraumatic stress disorder. J. Clin. Psychiatry64(10), 1230–1236 (2003).
   PubMed Web of Science ®Google Scholar
• Stein MB, Sherbourne CD, Craske MG et al. Quality of care for primary care patients with anxiety disorders. Am. J. Psychiatry161(12), 2230–2237 (2004).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders Text Revision. American Psychiatric Press, WA, USA (2000).
   Google Scholar
• McFarlane AC. The longitudinal course of posttraumatic morbidity. The range of outcomes and their predictors. J. Nerv. Ment. Dis.176(1), 30–39 (1988).
   PubMed Web of Science ®Google Scholar
• Heinrichs M, Wagner D, Schoch W et al. Predicting posttraumatic stress symptoms from pretraumatic risk factors: a 2-year prospective follow-up study in firefighters. Am. J. Psychiatry162(12), 2276–2286 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen H, Jotkowitz A, Buskila D et al. Post-traumatic stress disorder and other co-morbidities in a sample population of patients with irritable bowel syndrome. Eur. J. Intern. Med.17(8), 567–571 (2006).
   PubMedGoogle Scholar
• Boscarino JA. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. Ann. NY Acad. Sci.1032, 141–153 (2004).
   PubMed Web of Science ®Google Scholar
• Grieger TA, Cozza SJ, Ursano RJ et al. Posttraumatic stress disorder and depression in battle-injured soldiers. Am. J. Psychiatry163(10), 1777–1783; quiz 1860 (2006).
   PubMed Web of Science ®Google Scholar
• Bernal M, Haro JM, Bernert S et al. Risk factors for suicidality in Europe: results from the ESEMED study. J. Affect. Disord. (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch. Gen. Psychiatry56(7), 617–626 (1999).
   PubMed Web of Science ®Google Scholar
• Fichtner CG, Arora RC, O’Connor FL, Crayton JW. Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response. Life Sci.54(3), PL39–PL44 (1994).
   PubMedGoogle Scholar
• Fichtner CG, O’Connor FL, Yeoh HC, Arora RC, Crayton JW. Hypodensity of platelet serotonin uptake sites in posttraumatic stress disorder: associated clinical features. Life Sci.57(2), PL37–PL44 (1995).
   PubMed Web of Science ®Google Scholar
• Arora RC, Fichtner CG, O’Connor F, Crayton JW. Paroxetine binding in the blood platelets of post-traumatic stress disorder patients. Life Sci.53(11), 919–928 (1993).
   PubMedGoogle Scholar
• Maes M, Lin AH, Verkerk R et al. Serotonergic and noradrenergic markers of post-traumatic stress disorder with and without major depression. Neuropsychopharmacology20(2), 188–197 (1999).
   PubMed Web of Science ®Google Scholar
• Maguire K, Norman T, Burrows G, Hopwood M, Morris P. Platelet paroxetine binding in post-traumatic stress disorder. Psychiatry Res.77(1), 1–7 (1998).
   PubMedGoogle Scholar
• Spivak B, Vered Y, Graff E et al. Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. Biol. Psychiatry45(7), 840–845 (1999).
   PubMed Web of Science ®Google Scholar
• Lemieux AM, Coe CL. Abuse-related posttraumatic stress disorder: evidence for chronic neuroendocrine activation in women. Psychosom. Med.57(2), 105–115 (1995).
   PubMed Web of Science ®Google Scholar
• Yehuda R, Southwick S, Giller EL, Ma X, Mason JW. Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J. Nerv. Ment. Dis.180(5), 321–325 (1992).
   PubMed Web of Science ®Google Scholar
• Kosten TR, Mason JW, Giller EL, Ostroff RB, Harkness L. Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder. Psychoneuroendocrinology12(1), 13–20 (1987).
   PubMed Web of Science ®Google Scholar
• Denolle T, Sassano P, Allain H et al. Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients. Fundam. Clin. Pharmacol.16(6), 527–535 (2002).
   PubMed Web of Science ®Google Scholar
• Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J. Nerv. Ment. Dis.177(9), 546–550 (1989).
   PubMed Web of Science ®Google Scholar
• Southwick SM, Paige S, Morgan CA III et al. Neurotransmitter alterations in PTSD: catecholamines and serotonin. Semin. Clin. Neuropsychiatry4(4), 242–248 (1999).
   PubMedGoogle Scholar
• Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress. Anxiety16(1), 4–13 (2002).
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry180, 396–404 (2002).
   PubMed Web of Science ®Google Scholar
• Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. (415), 24–30 (2002).
   Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry178, 234–241 (2001).
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry62(11), 869–877 (2001).
   PubMed Web of Science ®Google Scholar
• Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin. Ther.21(2), 296–308 (1999).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry52(12), 1166–1174 (2002).
   PubMed Web of Science ®Google Scholar
• Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin. Ther.25(8), 2138–2154 (2003).
   PubMed Web of Science ®Google Scholar
• Venlafaxine XR, prescribing information. Wyeth Pharmaceuticals Inc., PA, USA .
   Google Scholar
• Bitsios P, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berl.)143(3), 286–292 (1999).
   PubMedGoogle Scholar
• Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress. Anxiety7(Suppl. 1), 24–32 (1998).
   PubMedGoogle Scholar
• Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: a comparative analysis. Hum. Psychopharmacol.19(1), 9–16 (2004).
   PubMedGoogle Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LP et al. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur. J. Clin. Pharmacol.59(12), 883–891 (2004).
   PubMed Web of Science ®Google Scholar
• Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs18(8), 505–520 (2004).
   PubMed Web of Science ®Google Scholar
• Muth EA, Haskins JT, Moyer JA et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol.35(24), 4493–4497 (1986).
   PubMed Web of Science ®Google Scholar
• Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann. Clin. Psychiatry9(3), 157–164 (1997).
   PubMedGoogle Scholar
• Entsuah R, Chitra R. A benefit–risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol. Bull.33(4), 671–676 (1997).
   PubMed Web of Science ®Google Scholar
• Davidson J, Rothbaum BO, Tucker P et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J. Clin. Psychopharmacol.26(3), 259–267 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson J, Baldwin D, Stein DJ et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch. Gen. Psychiatry63(10), 1158–1165 (2006).
   PubMed Web of Science ®Google Scholar
• Brady K, Pearlstein T, Asnis GM et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA283(14), 1837–1844 (2000).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry58(5), 485–492 (2001).
   PubMed Web of Science ®Google Scholar
• Tucker P, Zaninelli R, Yehuda R et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry62(11), 860–868 (2001).
   PubMed Web of Science ®Google Scholar
• Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry158(12), 1982–1988 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Landerman LR, Farfel GM, Clary CM. Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol. Med.32(4), 661–670 (2002).
   PubMed Web of Science ®Google Scholar
• Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. J. Clin. Psychiatry63(3), 199–206 (2002).
   PubMed Web of Science ®Google Scholar
• Deneys ML, Ahearn EP. Exacerbation of PTSD symptoms with use of duloxetine. J. Clin. Psychiatry67(3), 496–497 (2006).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry179, 15–22 (2001).
   PubMed Web of Science ®Google Scholar
• Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl.)177(3), 280–288 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson J, Pearlstein T, Londborg P et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am. J. Psychiatry158(12), 1974–1981 (2001).
   PubMed Web of Science ®Google Scholar
• Londborg PD, Hegel MT, Goldstein S et al. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J. Clin. Psychiatry62(5), 325–331 (2001).
   PubMed Web of Science ®Google Scholar
• Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol. Bull.31(2), 439–447 (1995).
   PubMed Web of Science ®Google Scholar
• Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J. Clin. Psychopharmacol.11(4), 233–236 (1991).
   PubMed Web of Science ®Google Scholar
• Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiatry56(10), 450–458 (1995).
   PubMed Web of Science ®Google Scholar
• Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J. Affect. Disord.56(2–3), 171–181 (1999).
   PubMed Web of Science ®Google Scholar
• Smajkic A, Weine S, Djuric-Bijedic Z et al. Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. J. Trauma. Stress14(3), 445–452 (2001).
   PubMedGoogle Scholar
• Hamner MB, Frueh BC. Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. Int. Clin. Psychopharmacol.13(5), 233–234 (1998).
   PubMedGoogle Scholar
• Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry61(4), 276–281 (2000).
   PubMed Web of Science ®Google Scholar
• Pae CU, Patkar AA. Paroxetine: current status in psychiatry. Expert. Rev. Neurother.7(2), 107–120; Erratum in: Expert Rev. Neurother.7(3), 313–314 (2007).
   PubMedGoogle Scholar
• Andreski P, Chilcoat H, Breslau N. Post-traumatic stress disorder and somatization symptoms: a prospective study. Psychiatry Res.79(2), 131–138 (1998).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol.1–12 (2005).
   Google Scholar
• Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM96(5), 369–374 (2003).
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Rapid onset of action of venlafaxine. Int. Clin. Psychopharmacol.10(Suppl. 2), 21–27 (1995).
   PubMedGoogle Scholar